WOONSOCKET, R.I., March 16, 2023 /PRNewswire/ -- CVS Health (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty and a half cents ($0.605 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 1, 2023, to holders of record on April 21, 2023.
About CVS Health
CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.
Last Trade: | US$67.26 |
Daily Change: | 0.66 0.99 |
Daily Volume: | 2,234,755 |
Market Cap: | US$84.750B |
February 17, 2025 February 12, 2025 November 19, 2024 November 18, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load